WaveWriter Alpha™ neurostimulation system: Two Boston Scientific WaveWriter Alpha™ Implantable Pulse Generators (IPGs) will be implanted and connected to CoverEdge™ or CoverEdge™ X 32 Surgical Paddle Leads. The leads are positioned to enable targeted stimulation of the spinal cord to optimize control of urinary functions.
Study summary
This clinical trial aims to assess the preliminary safety and efficacy of Epidural Electrical Stimulation (EES) therapy in managing lower urinary tract dysfunction in individuals with sub-acute or chronic spinal cord injury (SCI). The study evaluates the therapy's potential to improve urinary function and prevent neurogenic detrusor overactivity, ultimately seeking to enhance quality of life for individuals with SCI.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age 18 or older;
* Must provide and sign the Informed Consent Form prior to any study-related procedures;
* Spinal cord injury lesion level above T11 (inclusive);
* SCI graded as AIS- B, C or D;
* SCI ≥ 6 months;
* Confirmed lower urinary tract dysfunction during urodynamic assessment (NDO, DSD);
* Intolerant, refractory or inefficient to conservative treatment options such as medications and behavioural management;
* Using intermittent self-catheterization;
* Stable medical, physical and psychological condition as considered by the investigators;
* Able to understand and interact with the study team in French or English;
* Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments;
Exclusion Criteria:
* Botulinum toxin vesical injections in the previous 6 months;
* Presence of non-pharmacological treatments for lower urinary tract dysfunction (e.g. sacral nerve stimulation);
* Does have or needs a suprapubic catheter or bladder indwelling catheter;
* Presence of upper urinary tract dilatation or bladder or renal stones;
* Presence of urethral stricture or significant benign prostate hyperplasia;
* Presence of significant pressure ulcers;
* Previous lower urinary tract surgery;
* Presence of Autonomic Dysreflexia during urodynamic test;
* Recurrent and symptomatic urinary tract infection (more than 3 per year);
* Presence of intrathecal baclofen pump;
* Diseases and conditions that would increase the morbidity and mortality of spinal surgery;
* Other clinically significant concomitant disease states (e.g., syringomyelia, bladder cancer, renal failure, hepatic dysfunction, cardiovascular disease, etc.);
* The inability to withhold antiplatelet/anticoagulation agents perioperatively;
* Presence of pacemakers for cardiac conditions;
* Other conditions that would make the subject unable to participate in testing in the judgement of the investigators;
* Women who are pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding;
* Lack of acceptable or highly effective method of contraception for women of childbearing capacity;
* Intention to become pregnant during the course of the study;
* Inability to follow the procedures of the study, e.g. due to language problems, mental illness, psychological disorders, or dementia of the participant;
* Participation in another study with investigational drug or device within the 30 days preceding and during the present study;
* Have any indication that would require Magnetic Resonance Imaging (MRI)
* Is the investigator himself, his/her family members, employees or other dependent persons.
Primary outcome measure(s)
Occurrence of serious adverse events and adverse events. — From enrolment through study completion, an average of 10 months. Occurrence of serious adverse events and adverse events that are deemed related or possibly related to the use of the investigational.
Trial sites (1)
Facility
City
Region
Status
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne
Canton of Vaud
Recruiting
More Ecole Polytechnique Fédérale de Lausanne trials in Switzerland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.